Exozymes (EXOZ) Non-Current Deffered Revenue (2023 - 2026)
Exozymes (EXOZ) posted quarterly Non-Current Deffered Revenue of $90365.0 for Q4 2025, down 26.88% year-over-year from $123579.0 in Q4 2024, and down 12.32% quarter-over-quarter from $103065.0 in Q3 2025.
Exozymes (EXOZ) Non-Current Deffered Revenue (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Non-Current Deffered Revenue for 3 consecutive years, with $90365.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue fell 26.88% year-over-year to $90365.0; the TTM figure through Dec 2025 stood at $90365.0 (down 26.88% YoY), while the FY2025 annual figure was $90365.0, down 26.88% from the prior year.
- Non-Current Deffered Revenue slipped to $90365.0 in Q4 2025 per EXOZ's latest filing, from $103065.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $140703.0 in Q4 2023 and bottomed at $90365.0 in Q4 2025.
- Historically, Non-Current Deffered Revenue has averaged $117284.1 across 3 years, with a median of $116119.0 in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue slipped 12.17% — and 2025, when it declined 26.88%.
- Exozymes' Non-Current Deffered Revenue stood at $140703.0 in 2023, then retreated by 12.17% to $123579.0 in 2024, then slipped by 26.88% to $90365.0 in 2025.
- Business Quant data shows EXOZ's Non-Current Deffered Revenue at $90365.0 in Q4 2025, $103065.0 in Q3 2025, and $116119.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | 66,382.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66,382.00 |
| Dec 31, 2025 | 90,365.00 |
| Sep 30, 2025 | 103,065.00 |
| Jun 30, 2025 | 116,119.00 |
| Mar 31, 2025 | 110,123.00 |
| Dec 31, 2024 | 123,579.00 |
| Sep 30, 2024 | 137,035.00 |
| Dec 31, 2023 | 140,703.00 |